ArticleBrain and behavior2018
Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis.
Article in Brain and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- A narrative review of the economic burden of myelin oligodendrocyte glycoprotein antibody-associated disease and analogous conditions.Frontiers in neurology · 2025Pooled it
- Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).Journal of neurology · 2021Pooled it
- A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD.International journal of chronic obstructive pulmonary diseaseTrial
- Cost Analysis of Immunoglobulin Maintenance Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy in Spain.PharmacoEconomics - open · 2026Article
- Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.Journal of neurology · 2022Article
- Using a scenario approach to assess for the current and future demand of immunoglobulins: An interview and literature study from The Netherlands.Transfusion medicine (Oxford, England) · 2022Review
- Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia.Blood advances · 2022Article
- Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.Muscle & nerve · 2021Review
- The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP.Frontiers in neurology · 2021Article
- High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.European journal of pediatrics · 2020Article
- Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.World journal of gastroenterology · 2020Article
- Article
- Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis.American health & drug benefits · 2019Article
- Connected drug delivery devices to complement drug treatments: potential to facilitate disease management in home setting.Medical devices (Auckland, N.Z.) · 2019Review
- Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis.Brain and behavior · 2018Article
- Article
- Healthcare utilization and productivity losses associated with CIDP: results from an international survey.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prior clinical trials have suggested that home-based Ig treatment in multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and its variant Lewis-Sumner syndrome (LSS) is safe and effective and is less costly than hospital-administered intravenous immunoglobulin (IVIg). Methods: A French prospective, dual-center, cost minimization analysis was carried out to evaluate IVIg administration (5% concentrated) at home versus in hospital with regard to costs, patients' autonomy, and patients' quality of life. The primary endpoint was the overall cost of treatment, and we adopted the perspective of the payer (French Social Health Insurance). Results: Twenty-four patients aged 52.3 (12.2) years were analyzed: nine patients with MMN, eight with CIDP, and seven with LSS. IVIg (g/kg) dosage was 1.51 ± 0.43 in hospital and 1.52 ± 0.4 at home. Nine-month total costs per patient extrapolated to 1 year of treatment were €48,189 ± 26,105 versus €91,798 ± 51,125 in the home and hospital groups, respectively ( Discussion: The switch from hospital-based to home-based IVIg treatment for patients with immune neuropathy represents potentially significant savings in the management of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.